Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro

Solubilization of poorly soluble PDT agent, meso-tetraphenylporphin, in plain or immunotargeted PEG-PE micelles results in dramatically improved cancer cell killing in vitro
复制标题

DOI:
10.1016/j.ejpb.2005.09.010
复制
发表时间:
2006-04-01
影响因子:
4.9
通讯作者:
Torchilin, VP
Torchilin, VP
中科院分区:
医学2区
文献类型:
--
作者:
Roby, A;Erdogan, S;Torchilin, VP

文献摘要

被引文献

相似文献

用聚乙二醇/磷脂酰乙醇胺偶联物(PEG-PE)制备的非靶向和肿瘤靶向聚合物胶束,有效地溶解了难溶性光动力治疗(PDT)药物中四苯基卟啉(TPP)。将TPP包封在peg - pe基胶束和免疫胶束中(含有抗癌单克隆2C5抗体),在PDT条件下对小鼠(LLC, b16)和人(MCF-7, BT20)癌细胞的体外抗癌作用显著提高。为此,将细胞与TPP或TPP负载的PEG-PE胶束/免疫胶束孵育6或18小时,然后光照射30分钟。光毒性作用取决于TPP浓度和免疫胶束的特异性靶向。在pdt处理的培养中,细胞凋亡水平增加。将抗癌2C5抗体附着在装载tpp的胶束上,在给定时间内提供了最大水平的细胞杀伤。本研究结果表明,含ppp的PEG-PE胶束可能是一种实用的PDT光敏剂配方。(c) 2006 Elsevier B.V.版权所有
Poorly soluble photodynamic therapy (PDT) agent, meso-tetratphenylporphine (TPP), was effectively solubilized using non-targeted and tumor-targeted polymeric micelles prepared of polyethylene glycol/phosphatidyl ethanolamine conjugate (PEG-PE). Encapsulation of TPP into PEG-PE-based micelles and inimunomicelles (bearing an anti-cancer monoclonal 2C5 antibody) resulted in significantly improved anticancer effects of the drug at PDT conditions against murine (LLC, B 16) and human (MCF-7, BT20) cancer cells in vitro. For this purpose, the cells were incubated for 6 or 18 h with the TPP or TPP-loaded PEG-PE micelles/immunomicelles and then light-irradiated for 30 min. The phototoxic effect depended on the TPP concentration and specific targeting by immunomicelles. An increased level of apoptosis was shown in the PDT-treated cultures. The attachment of the anti-cancer 2C5 antibodies to TPP-loaded micelles provided the maximum level of cell killing at a given time. The results of this study showed that TPP-containing PEG-PE micelles may represent a useful formulation of the photosensitizer for practical PDT. (c) 2006 Elsevier B.V. All rights reserved.